



October 4, 2007

Contact Details:

Email : research@dsl.ie

Tel : +353 1 633 3800
info@dsl.ie Fax : +353 1 677 4708

EQUITIES	Close	Change	% +/-	P/E '07	YTD
ISEQ	8368	↑ 123	1.49%	14.1	-11.06%
FTSE 100	6535	↑ 35	0.54%	13.2	5.05%
DAX 30	7959	↑ 13	0.16%	14.2	20.65%
DOW	13968	↓ -79	-0.56%	15.2	12.07%
NASDAQ	2729	↓ -18	-0.64%	26.1	13.01%
S&P	1540	↓ -7	-0.46%	15.9	8.55%

CURRENCIES & RATES	Euro	Dollar	Stg	Yen
Euro	1.0000	1.4097	0.6947	164.3600
Dollar	1.4097	1.0000	2.0288	116.6000
Sterling	0.6947	2.0288	1.0000	236.5400
Interest Rates (%)	4.0000	5.2500	5.7500	0.5000
Oil (Nymex)	80.0500			

This Week's Research
Tesco
Total Produce

Today's Research
Intel

Breaking News

Intel (\$25.60) Benefits from strong PC demand Stephen Taylor

- **Semiconductor industry:** On 01/10/07, The Semiconductor Industry Association (SIA) announced that worldwide sales of semiconductors rose sharply in August by 4.9% to \$21.5bn and a 4.5% increase on July's figure due to increased demand for PCs and notebooks. The SIA noted that PC growth in 2007 had been 'very solid' and as a result Credit Suisse and the Gartner Group have raised upward their forecasts for growth in unit sales of PCs from 11% to 13% in 2007.
- **Raised guidance:** PCs account for approximately 40% of all semiconductor sales for which Intel is the largest supplier of semiconductors and growth is being driven by surging demand from emerging market economies such as China and India where Intel is growing market share. Further evidence of demand for PCs and notebooks was seen in Dell's recent second quarter results, which showed that revenue increased by 7% to \$14.8bn beating expectations. Intel also raised 3Q guidance and now expects revenue to grow by up to 13% to \$9.8bn from 12% previously and forecasts its gross margin to be at the upper half of its previous range of 52% plus or minus a couple of points.
- **Revenue breakdown:** A geographical breakdown of Intel's revenue from its second quarter results shows that 62% is generated from the Asia-Pacific region with only 21% from the US and 17% in Europe. While all the signs are at the moment that the US economy is slowing due to the ongoing housing slump, Intel should be well insulated from this due to its sizeable and increasing exposure to emerging markets.
- **New products:** On 18/09/07, Intel announced plans to sell a new line of faster computer chips named Penryn in an attempt to extend its lead in the semiconductor industry over its closest competitor Advanced Micro Devices. The new processors will be available from November which is a month ahead of analyst had expectations. The Penryn chip will use Intel's existing chip design, only with smaller wires that can make circuits more efficient and should help Intel increase its market share.
- **Upside potential:** With Intel expected to generate EPS growth of 22% during 2008 its P/E for the same period of 18x appears undemanding and is at a discount to its historical average of 21.5x and its peer group of 20x. In light of the group's growth prospects due to its exposure to emerging market demand we feel that a multiple of 21x would be more appropriate. As result we generate our 12 month price target of \$29.50 based on 21x 2008 forecasted eps of \$1.40 and initiate coverage of the stock with a buy rating: **BUY**.

Breaking News

United Drug issues upbeat trading statement

United Drug has issued a positive trading statement this morning and said it had experienced good trading conditions and strong revenue growth in each of its four divisions during 2007. As a result, the company expects operating profit and earnings for the year ending 30/09/07 to show double digit growth over the same period last year and ahead of current market expectations. United Drug commented that it had made significant progress in its Supply Chain Services division towards the development of a European pharmaceutical contract business. The group's Medical & Scientific division is also expected to report very strong growth due to a continued positive performance in the its underlying business in Ireland and the UK which has been complemented by the acquisition of Pyramed. United Drug pointed out that it remains positive about the fundamental dynamics driving the demand for healthcare goods and services in core markets, while it continues to see opportunities to expand its manufacturer services businesses, both organically and through acquisitions.

Ryanair reports strong passenger numbers for September

Ryanair reported a strong set of passenger numbers for September and ahead of expectations. Ryanair said that its passenger numbers grew by 23% to 4.35m when compared with the same period last year and ahead of the 20% consensus. The group's load factor fell slightly to 85% from 86% previously. Ryanair's passenger numbers for October should be further underpinned following its announcement that it will add 70 new routes during October with additional destinations to be served from Barcelona, Dublin, Dusseldorf, Italy and Stockholm.

KBC reiterates profit guidance

KBC said today that it is 'on track' to deliver on its financial targets for the 2006-2009 period. KBC aims to increase earnings per share by at least 12% a year through 2009, with a return on equity of at least 15%. The group also pointed out that it is 'well-positioned' to cope with the tougher credit environment and that it expects to have no material liquidity or solvency issues.

Business Press

- Deutsch Bank takes hit (WSJ)
- Microsoft plays a new tune, revising an iPod competitor (WSJ)
- Possible bid war hits Tom Tom (IT)
- Irish stocks outperform rest of Europe (IT)

Investment Press

- **Internet M&A:** In July 2005, Rupert Murdoch snapped up MySpace for \$580m. In September of the same year Ebay had a \$2.6bn flutter on internet phone group Skype. Two years later, how do the gamblers stack up?

Disclaimer: The information in this document has been obtained from sources, which we believe to be reliable. We cannot guarantee its accuracy or completeness. It does not constitute a solicitation for the purchase or sale of any investment. Any person acting on the information contained in this document does so at their own risk. Recommendations in this document may not be suitable for all investors. Individual circumstances should be considered before a decision to invest is taken. Investors should note the following: Past experience is not necessarily a guide to future performance. The value of investments may fall or rise against investors' interests. Income levels from investments may fluctuate. Changes in exchange rates may have an adverse effect on the value of, or income from, investments denominated in foreign currencies. Dolmen Securities is a Member Firm of the London Stock Exchange, and is authorised by the Financial Regulator under the Investment Intermediaries Act 1995. Dolmen Stockbrokers is a Member Firm of The Irish Stock Exchange, The London Stock Exchange, and is authorised by the Financial Regulator under the Stock Exchange Act 1995.

DOLMEN SECURITIES → Website : www.dolmenstockbrokers.ie

75 St. Stephen's Green, Dublin 2, Ireland.
45 South Mall, Cork, Ireland.

Theatre Court, Mallow Street, Limerick, Ireland

• Tel : +353 1 633 3800

• Tel : +353 21 422 2122

• Tel : +353 61 436 500

• Fax : +353 1 677 7044

• Fax : +353 21 422 2123

• Fax : +353 61 436 599

• Email : info@dsl.ie

• Email : cork@dsl.ie

• Email : limerick@dsl.ie



DOLMEN SECURITIES

Disclosures

This report has been prepared by Dolmen Stockbrokers ('Dolmen') for information purposes only to assist investors to make their own investment decisions and is not intended to and does not constitute personal recommendations nor provide the sole basis for any evaluation of the securities discussed. Specifically the information contained in this report should not be taken as an offer or solicitation of investment advice or, encourage the purchase or sale of any particular security, option, future or other derivative investment. Not all recommendations are necessarily suitable for all investors and Dolmen recommend that specific advice should always be sought prior to investment, based on the particular circumstances of the investor.

Although the information in this report has been obtained from sources, which Dolmen believes to be reliable and all reasonable efforts are made to present accurate information Dolmen give no warranty or guarantee as to, and do not accept responsibility for, the correctness, completeness, timeliness or accuracy of the information provided or its transmission. Nor shall Dolmen, or any of its employees, directors or agents, be liable to for any losses, damages, costs, claims, demands or expenses of any kind whatsoever, whether direct or indirect, suffered or incurred in consequence of any use of, or reliance upon, the information. Any person acting on the information contained in this report does so entirely at his or her own risk.

All estimates, views and opinions included in this report constitute Dolmen's judgment as of the date of the report but may be subject to change without notice. Changes to assumptions may have a material impact on any recommendations made herein.

Unless specifically indicated to the contrary this report has not been disclosed to the covered issuers(s) in advance of publication.

Past performance is not necessarily a guide to future returns. The value of investments and the income from them can fall as well as rise. Investments denominated in foreign currencies are subject to fluctuations in exchange rates, which may have an adverse affect on the value of the investments, sale proceeds, and on dividend or interest income. Investors may not necessarily recoup the full value of their original investment. Investors should be aware that forwarding looking statements and forecasts may not be realised.

This report may not be reproduced (in whole or in part) altered, transmitted or made available to any other person without the prior written permission of Dolmen.

Dolmen Securities is a Member Firm of the London Stock Exchange, and is authorised by the Financial Regulator under the Investment Intermediaries Act 1995. Dolmen Stockbrokers is a Member Firm of The Irish Stock Exchange, The London Stock Exchange, and is authorised by the Financial Regulator under the Stock Exchange Act 1995.

Conflicts of Interest & Share Ownership Policy

Dolmen, its employees, directors or related companies, may have a shareholding in the securities (or related investments/ derivatives) of certain companies covered in this report, or may provide/ solicit investment banking or other services to/ from them.

It is noted that research analysts' compensation is impacted upon by overall firm profitability and accordingly may be affected to some extent by revenues arising other Dolmen business units including Corporate Finance, Fund Management and Stockbroking. Revenues in these business units may derive in part from the recommendations or views in this report. Notwithstanding, Dolmen is satisfied that the objectivity of views and recommendations contained in this report has not been compromised.

Dolmen permits research analysts to own shares and/ or derivative positions in issuers they publish research, views and recommendations on and accordingly analysts involved in the production of this report may own stocks in a company covered in it. Any own account staff trading is undertaken in strict compliance with Dolmen's own account internal rules and therefore Dolmen is satisfied that the impartiality of research, views and recommendations remains assured.

Analyst Certification

Each research analyst responsible for the content of this report, in whole or in part, certifies that: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Stuart Draper, Carl Bourke and Stephen Taylor are responsible for the production of this report. Stuart Draper is Head of Research and Carl Bourke & Stephen Taylor are equity analysts.

For US Persons Only

This report is only provided in the US to major institutional investors as defined by s. 15 a-6 of the Securities Exchange Act, 1934 as amended. A US recipient of this report shall not distribute or provide this report or any part thereof to any other person.